Observational studyMedicine2015
Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan.
Observational study in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Risks of colorectal and extracolonic cancers following colorectal cancer: a systematic review and meta-analysis.JNCI cancer spectrum · 2025Pooled it
- Pooled it
- Risk of extracolonic second primary cancers following a primary colorectal cancer: a systematic review and meta-analysis.International journal of colorectal disease · 2022Pooled it
- Undifferentiated pelvic sarcoma 5 years post-radiochemotherapy for rectal adenocarcinoma: A case report.Oncology letters · 2026Article
- The relationship between ovarian and colorectal cancers: a systematic review and meta-analysis.Korean journal of clinical oncology · 2025Article
- Article
- Incidence, Risk and Trends of Multiple Primary Cancers in Patients With Colorectal Cancer: Evidence From the South Australian Cancer Registry.Cancer medicine · 2025Article
- Melanoma and Colorectal Cancer as Second Primary Cancers: A Scoping Review of Their Association and the Underlying Biological, Lifestyle, and Genetic Factors.Journal of gastrointestinal cancer · 2025Article
- Risk of Gynaecological Cancers as Second Primary in Non-gynaecological Cancer Survivors: A Retrospective Cohort Study.Journal of obstetrics and gynaecology of India · 2025Article
- Prognosis and clinicopathological features of patients with early-onset and late-onset colorectal cancer with second primary malignancies.Journal of gastroenterology and hepatology · 2025Article
- Synchronous Primary Gallbladder and Colon Adenocarcinoma: A Case Report and Systematic Literature Review.Cureus · 2024Article
- Association between chemotherapy for surgically treated rectal cancer and second primary endometrial cancer.Scientific reports · 2024Article
- Second primary common bile duct neuroendocrine tumor after 10 years in a patient with rectal adenocarcinoma: A case report.Caspian journal of internal medicine · 2024Article
- Relevance of the Hoover´s signal and the Babinski´s test for the diagnosis of functional hemiparesis.Caspian journal of internal medicine · 2024Article
- Risk prediction of second primary malignancies in patients after rectal cancer: analysis based on SEER Program.BMC gastroenterology · 2023Article
- Exploring the pathogenesis of colorectal carcinoma complicated with hepatocellular carcinoma via microarray data analysis.Frontiers in pharmacology · 2023Article
- Article
- Use of multikinase inhibitors/lenvatinib in patients with synchronous/metachronous cancers coinciding with radioactive-resistant differentiated thyroid cancer.Cancer medicine · 2022Review
- Article
- Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.Experimental and therapeutic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study is to determine the features of second primary malignancies (SPMs) among patients with prior colorectal cancer (CRC) using a nationwide population-based dataset.Patients with CRC newly diagnosed between 1996 and 2011, and >1 year of follow-up were recruited from the Taiwan National Health Insurance database. Standardized incidence ratios (SIRs) of SPMs in patients with CRC were calculated.During the 16-year study period, 4259 SPMs developed among 98,876 CRC patients. The median duration of follow-up was 4.03 years. The SIR for all SPMs was 1.13 (95% confidence interval = 1.10-1.17). Compared with the general population, a higher incidence of thyroid, prostate, ovarian, and hematologic malignancies developed among patients with colon cancer, whereas the risk for bone and soft tissue cancers increased among patients with rectal cancer. The risk for breast, bladder, kidney, lung, and uterine cancers was significantly higher in patients with colon and rectal cancers than the general population. The risk for liver and biliary tract cancers declined in patients with rectal cancer. Based on multivariate analysis among patients with CRC, age ≥70 years, men, chronic obstructive pulmonary disease (COPD), cirrhosis, and dyslipidemia were independent predictors of an SPM.In conclusion, patients with CRC were at increased risk for a second cancer. The pattern of SPMs was distinct between patients with colon and rectal cancer. Age, men, COPD, cirrhosis, and dyslipidemia were independent risk factors for SPMs. Surveillance and education should be provided for survivors with respect to risk for SPMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.